Dare Bioscience Inc (DARE)
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
$0.70+2.66%
Close 2026-10-30 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
Research Workspace
Put DARE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Revenue growth to at least $7.4M in FY27: Comparison needs review.
View ThesisMiddle-of-the-pack management execution.
View ManagementThis stock is highly volatile — it swings about 2% on a typical day and fell roughly 80% in its worst 12-month stretch.
View RiskDARE’s growth case rests on expanding revenue, though the desk lacks a multi-quarter growth trajectory. Its latest quarter beat on GAAP earnings, but the company remained unprofitable. DARE trades at 28× sales versus the 10× peer median, near its own 26× history. The price is roughly in line with the growth we forecast. Our model puts the next-quarter miss probability at 40%. The FY27 revenue-growth comparison needs review, so it is not a confirmed breach. Peer multiples imply a price about 9% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-30. DARE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 4 analysts currently covering DARE (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare DARE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| DARE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put DARE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Launch and grow DARE to PLAY Sildenafil Cream product revenue
Earnings call highlights commercial launch milestones for DARE to PLAY.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Threatens: Capital allocation via Regulation A equity offerings
Q2 EPS miss indicates potential cash flow issues.
Threatens: Capital allocation via Regulation A equity offerings
Capital allocation may dilute existing shareholder value.
Advances: Advance clinical pipeline with Ovaprene and DARE-HPV studies
Ovaprene data timeline aligns with clinical pipeline advancement.
Advances: Launch and grow DARE to PLAY Sildenafil Cream product revenue
Earnings beat indicates strong revenue growth potential.
Advances: Launch DARE to PLAY product revenue
Earnings beat indicates strong product performance.
Advances: Launch DARE to PLAY product revenue
Product launch news directly supports revenue objectives.